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Introduction: Novel therapeutic compounds are needed for prostate cancer
(CaP), given the limitations of already used drugs and the disease’s mortality,
often attributed to castrate resistance. Tissue kallikrein and kallikrein-related
peptidases (KLKs) form a family of serine proteases aberrantly expressed and
broadly implicated in human malignancies. In CaP, KLKs participate in the pro-
motion of cell proliferation, extracellular matrix degradation, tumour cell
invasion and metastasis.
Areas covered: This review discusses the different ways of inhibiting, modu-
lating and exploiting KLK activity and/or expression as emerging CaP thera-
peutics. KLKs are targeted by diverse naturally occurring substances,
including proteinaceous inhibitors, low-molecular-weight peptides and Zn2+.
Synthetic KLK inhibitors include protein/peptide-based inhibitors and small
molecules. A re-engineered serpin-based KLK inhibitor is under evaluation
in first-in-human trials as a CaP therapeutic, whereas additional potent and
selective KLK inhibitors with relevance to CaP have been synthesized.
KLK3-activated pro-drugs have entered Phase I and Phase II clinical trials as
therapeutics for prostate tumours. The KLK3-based PROSTVAC vaccine is
evaluated in Phase III clinical trials. Targeting KLK expression via RNA interfer-
ence methods could represent another promising therapeutic approach
for CaP.
Expert opinion: Apart from their immense biomarker potential, KLKs also
hold promise as the basis of novel CaP therapeutics.
Keywords: aptamers, gene expression targeting, imaging, immunotherapy, kallikrein-related
peptidases, kallikreins, microRNAs, pro-drugs, prostate cancer, protease inhibitor,
prostate-specific antigen, serine proteases, small-interfering RNA, tissue kallikrein
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1. Introduction
Tissue kallikrein (KLK1) and kallikrein-related peptidases (KLK2 -- KLK15) form a
multifaceted group of secreted serine proteases, referred to as KLKs. KLK genes
form an uninterrupted ~ 300 kb long cluster on chromosome 19q13.3 --
q13.4 (Figure 1), whereas plasma kallikrein (KLKB1) is located on 4q35 and is
not closely related, in terms of structure and function, to KLKs [1-4]; for this reason
KLKB1 will not be discussed further in this review.
KLKs form the largest group of serine proteases in the human genome and are
characterised by common structural properties. The five coding exons of
KLK1 -- KLK15 genes encode for pre-pro-protein molecules bearing the signal
peptide, in order to be secreted as pro-enzymes that will be ultimately cleaved to
produce the active (chymo)trypsin-like protease (Figure 1) [2-5]. KLKs possess a
typical tertiary structure consisting of b-sheets that give rise to two b-barrels with
two solvent exposed a-helices. The common catalytic triad His57-Asp102-Ser195
(chymotrypsinogen numbering) is located on an active-site cleft, after the crossing
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point of the two b-barrels. This cleft hosts distinct subsites
that also interact with and align the substrate to the catalytic
triad [5-10].
Despite the common structural characteristics shared by
KLKs, these proteases act on an astoundingly diverse array
of substrates (Figure 1). KLKs can process extracellular matrix
(ECM) proteins, cell adhesion proteins, growth factors, cell
surface receptors, hormones and other proteases, including
pro-KLKs and matrix metalloproteinases (MMPs). The mul-
tifaceted activity of KLKs allows them to regulate central,
yet dissimilar, physiological processes such as blood pressure
regulation, skin desquamation, semen liquefaction and neuro-
nal remodelling [4-7,11-13].
For such a broad biological function to be achieved, KLKs
need to be firmly regulated at multiple levels. KLK transcrip-
tion is regulated by steroid hormones and methylation sta-
tus [5,14]. Post-transcriptionally, microRNAs (miRNAs) have
been identified as an imperative way of controlling KLK
expression [14]. At the post-translational level, pro-KLKs are
activated by other KLKs via cross-cleavage, including even
auto-cleavage (KLK activome) or by other peptidases [7,12,13].
Even after KLK activation, a final regulatory mechanism exists:
a wide-ranging ensemble of endogenous KLK inhibitors [15].
Nonetheless, the expression and/or activity of KLKs are
found to be deregulated in many pathologies. Non-malignant
conditions associated with KLK malfunction include, among
others, skin diseases, neurodegenerative diseases and
asthma [13,16]. KLKs have also become renowned for their
continuously reported implication in processes considered as
hallmarks of cancer, including tumour growth, angiogenesis,
invasion and metastasis [7,12,17]. In prostate cancer (CaP),
KLKs are involved in the promotion of cell invasiveness,
induction of tumour growth, facilitation of epithelial-to-mes-
enchymal transition (EMT), degradation of ECM and bone
metastasis [18]. Interestingly, every single kallikrein-related
peptidase has been proposed as a biomarker for at least one
human malignancy [17,19,20]. KLK3, or prostate-specific
antigen (PSA), as it is largely known, is the most widely
used biomarker in the clinic. Despite recent criticism, KLK3
testing is currently applied for the screening, diagnosis, prog-
nosis and treatment monitoring of CaP [21].
The continuing high incidence of CaP globally [22], the
decreased survival of patients suffering from metastatic dis-
ease [23] and the limitations of currently used therapies trans-
form the necessity of novel CaP drugs into a major clinical
priority. Taking into account the multifactorial involvement
of several KLK members in CaP pathobiology [18], it would
be rational to consider KLK activity and/or expression as a
promising target of personalised therapeutics.
2. Currently used therapeutics in CaP:
limitations and unmet medical needs
Androgen deprivation therapy (ADT) remains the golden
standard for the management of patients with advanced CaP
not suitable for definite treatment. ADT is also used as an
adjuvant therapy for high-risk localised CaP patients undergo-
ing radical radiotherapy and for confronting disease progres-
sion following initial treatment [24].
Medical castration using long-acting luteinising-hormone-
releasing hormone (LHRH) agonists (buserelin, goserelin, leu-
prorelin, triptorelin) and concomitant therapy with non-steroid
anti-androgens (nilutamide, flutamide, bicalutamide) is used to
generate castrate levels of serum testosterone. Additionally,
LHRH antagonists are effective in rapidly decreasing the testos-
terone levels without flare; however, due to histamine-mediated
side effects, they are currently FDA approved only for
metastatic and symptomatic CaP (abarelix) [25].
Article highlights.
. Several members of the cancer biomarker family of
tissue kallikrein and kallikrein-related peptidases (KLKs)
are significantly deregulated in prostate cancer (CaP)
and are implicated in the facilitation of prostate
tumorigenesis and disease progression through the
promotion of extracellular matrix degradation, tumour
cell invasion, angiogenesis and metastasis. Aberrant KLK
activity on other proteases, growth factors, cell surface
receptors and hormones promotes these tumour
promoting changes.
. KLKs are targeted by diverse naturally occurring
substances, including proteinaceous inhibitors,
low-molecular-weight peptides and Zn2+. Engineered
KLK inhibitors include protein/peptide-based inhibitors
and small-molecule inhibitors. MDPK67b is a
serpin-based inhibitor designed to block KLK2,
KLK4 and KLK14 activity and is under evaluation in
first-in-human trials as a CaP therapeutic. Sunflower
trypsin inhibitor-FCQR-Asn14 is another bioengineered
potent, selective, stable and bioavailable KLK4 inhibitor
which holds promise as a potential CaP therapeutic.
Modified short peptides, activity-blocking antibodies,
small-molecule inhibitors and aptamers that can target
CaP-associated KLKs (KLK1 -- 4, 7 and 14) have also
been developed.
. The KLK3-activated pro-drugs L-377,202 and
PRX302 have entered Phase I and Phase II clinical trials,
respectively, as therapeutics for prostate tumours and
have shown a favourable toxicity profile.
. The KLK3-based PROSTVAC vaccine has already
entered Phase III clinical trials for evaluation as a novel
immunotherapeutic for CaP. Immunotherapeutic
anti-KLK3 engineered antibodies have been developed.
KLK4 is also a promising candidate for
CaP immunotherapy.
. Targeting and restoring KLK expression via RNA
interference methods could represent another promising
therapeutic approach for CaP.
. KLK-based drugs have been developed for other
pathological conditions, including skin diseases
(KLK7 and multi-KLK inhibitors) and asthma
(anti-KLK1 monoclonal antibody).
This box summarises key points contained in the article.
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Despite chemical castration, the majority of patients progress
to lethal castrate-resistant prostate cancer (CRPC). Secondary
hormonal therapy for disease progression after ADT includes
anti-androgen withdrawal and/or switching to an alternative
anti-androgen (initial flutamide to bicalutamide and vice
versa) [24,25], novel therapeutic agents such as the CYP17
inhibitors ketoconazole [26] and abiraterone, approved for
chemotherapy-naı¨ve metastatic CRPC [27], as well as the novel
androgen receptor (AR) antagonist enzalutamide (EDV3100)
approved for docetaxel-treated metastatic CRPC [28]. First-line
chemotherapy for CRPC includes mitoxantrone, estramustine
and docetaxel; TAX-327 and SWOG 99-16 trials highlight
docetaxel survival benefits compared to mitoxantrone [29,30].
Recently, cabazitaxel was approved for the treatment of patients
with metastatic CRPC who progress despite docetaxel treat-
ment [31]. Focusing on the palliative therapy of CRPC patients
with bone metastasis, zoledronic acid [32], denosumab [33] and
radium-223 [34] have been approved and used in clinical prac-
tice. Finally, clinical trials of immunotherapy-based treatments
led to the approval of sipuleucel-T, an autologous cellular
immunotherapy approach for asymptomatic or minimally
symptomatic metastatic CRPC [35].
Although hormone therapy significantly improves the
progression-free survival of patients before developing CRPC,
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Figure 1. The common structural characteristics of KLKs at gene and protein levels, as well as a brief presentation of their
most well-characterised substrates are shown. A. The genomic localisation of KLK gene family on 19q13.3 -- q13.4 is shown.
The direction of transcription is indicated by the arrows. B. A schematic presentation of the common structural characteristic
of KLK genes (five coding exons, four introns and location of the catalytic triad codons). C. An overview of the pre-pro-protein
structure of KLKs (location of the signal peptide, pro-peptide, catalytic triad and mature enzyme) is shown. D. The most
commonly reported groups of KLK substrates (ECM proteins, seminal plasma components, blood components, growth factors/
hormones, proteases/enzymes, cell adhesion molecules/cell surface receptors) are shown.
ECM: Extracellular matrix; GH: Growth hormone; GHRH: Growth-hormone-releasing hormone; HGF: Hepatocyte growth factor; IGFBP: Insulin-like growth factor
binding protein; KLK: Tissue kallikrein and kallikrein-related peptidase; MMP: Matrix metalloproteinases; PARs: Protease-activated receptors; PTHrP: Parathyroid
hormone-related protein; TGFb: Transforming growth factor b; uPA: Urokinase-type plasminogen activator; uPAR: uPA receptor.
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it is accompanied by harmful side effects and a downgrade in
patients’ quality of life. Malfunctions of long-term ADT
include increased risk of diabetes mellitus, cardiovascular
disease and myocardial infarction, metabolic syndrome, hyper-
lipidemia, non-metastatic bone fractures, hot flashes, loss of
libido and erectile dysfunction. Additionally, chemotherapy
can only benefit patients’ survival on the order of months and
with numerous side effects, such as nephro- and hepato-toxicity,
low white blood cell counts and thus lower resistance to infec-
tions, thrombocytopenia, anaemia, fatigue, diarrhoea, nausea
and hair loss. Finally, immunotherapy via sipuleucel-T is con-
sidered a complex and expensive procedure [24,25].
3. KLKs: a family of promising therapeutic
targets for CaP
The expression of the majority of KLKs is significantly deregu-
lated in prostate tumours. KLK2 and KLK4 are significantly
overexpressed, at both the mRNA and protein levels, moving
from normal or benign prostate epithelium to high-grade pros-
tatic intraepithelial neoplasia (HGPIN) lesions and CaP [36-42].
Additionally, KLK14 and KLK15 expressions are also upregu-
lated in CaP compared to benign prostate tissues, as well as
in advanced disease [18]. Of significant interest, KLK3 expres-
sion is downregulated in CaP and HGPIN lesions compared
to benign and normal epithelium [40-43]. Although KLK3
downregulation contradicts with its elevated serum levels in
CaP patients, the disruption of prostate tissue architecture
that take place during the progression of prostate tumours is
responsible for its greater secretion into circulation. Moreover,
KLK5 and KLK7 expression levels are reduced in CaP [18].
Finally, increased methylation of KLK6 and KLK10 promoters
has been reported in CaP compared to benign epithelium [44].
The abovementioned deregulation of the majority of KLKs
triggers an irreversible impact upon their substrates [18]. Sev-
eral KLK members facilitate prostate tumorigenesis and dis-
ease progression through the development of an oncogenic
microenvironment for prostate cells (Figure 2).
KLKs are able to activate the IGF-IGFR axis in prostate
tissues. More precisely, KLK2 [45], KLK3 [45,46], KLK4 [47]
and KLK11 [48] cleave IGF-binding proteins and increase
IGFs availability in prostate microenvironment. This KLK-
mediated overactivation of IGF-IGFR signalling induces
mitogenic and anti-apoptotic stimuli in prostate cells which
are essential for prostate tumorigenesis [49,50]. Moreover,
KLK-related proteolytic activation of protease-activated
receptors (PARs), a G-protein-coupled cell surface receptor
family, launches intracellular cascades enhancing prostate
cell proliferation and migration. More precisely, KLK2 and
KLK4 have been documented to cleave PAR1 (KLK4) and
PAR2 (KLK2 and KLK4) leading to enhanced proliferation
of DU145 and PC3 cells through the activation of extracellu-
lar signal-regulated kinase (ERK) signalling [51,52]. Cleavage of
PAR1 and activation of PAR1-induced intracellular cascades
has also been attributed to KLK1. Treatment of DU145 cells
with KLK1 resulted in a PAR1-related induction of their
migration and invasiveness [53].
The expression of prostate-cancer related KLKs depends on
AR transcriptional activity and thus to the binding of AR to
KLK promoters. Androgen response elements have been iden-
tified for KLK2 -- KLK4 [5]. However, recent findings have
highlighted that AR activity is also significantly enhanced by
KLK2, KLK3 and KLK4 in prostate cells. More precisely,
KLK2 interaction with ARA70, an AR co-activator, was
found to be essential for AR transactivation in CaP cell lines
as well as the maintenance of AR activity despite the presence
of anti-androgens. Small-interfering RNA (siRNA)-mediated
silencing of KLK2 results in reduced cell growth and induces
apoptosis in CaP cell lines [54].
Focusing on KLK4, its overexpression in CaP is essential
for the maintenance of AR and mammalian target of rapamy-
cin (mTOR) signalling in prostate cells. Protein--protein
interactions between KLK4 and promyelocytic leukaemia
zinc finger protein (PLFZ), an inhibitor of AR and
mTOR1 pathways, suppress PLFZ stability and activity, facil-
itating in this way AR and mTOR1 mitogenic and anti-
apoptotic signalling. Knockdown of KLK4 expression in
CaP cells leads to reduced AR mRNA levels and transcrip-
tional activity, highlighting a positive feedback loop between
KLK4 and AR in CaP [55]. Additionally, KLK4-mediated acti-
vation of PAR1 in the surface of prostate stroma cells leads to
increased release of IL6 and the subsequent overactivation of
AR transcriptional activity, through ERK and signal trans-
ducer and activator of transcription 3 intracellular path-
ways [52,56,57]. Similarly, positive regulation of AR expression
levels has also been documented for KLK3. More precisely,
stable transfection of CaP cells with small hairpin RNA
(shRNA) against KLK3 was found to reduce both mRNA
and protein levels of AR, underlying the necessity of
KLK3 for AR signalling [58]. Moreover, KLK3 interacts with
ARA70 and stimulates ARA70-induced AR transactivation,
which leads to the increased cell growth of AR-positive CaP
cell lines [59]. The abovementioned positive feedback loop of
KLK2, KLK3 and KLK4 with AR signalling highlights their
significance for AR-related tumorigenic stimuli in prostate
cells and the maintenance of AR signalling in CRPC.
In CaP, KLKs are also well documented to promote ECM
protein degradation and thus to disrupt the physical barriers
protecting from cancer invasion and metastasis. KLK2 and
KLK3 have been found to directly cleave fibronectin and lam-
inin, whereas KLK14 is also able to cleave collagens I -- IV [18].
Moreover, KLK2 and KLK4 are able to stimulate ECM degra-
dation via the activation of plasmin and MMPs. More pre-
cisely, overexpression of KLK2 and KLK4 in CaP promotes
the accumulation of urokinase-type plasminogen activator
(uPA), due to increased cleavage of pro-uPA, leading to plas-
min and MMPs activation through uPA-uPA receptor
(uPAR) axis [60,61]. Moreover, KLK2 can also facilitate uPA-
uPAR system-related proteolysis by the degradation of plas-
minogen activator inhibitor-1 (PAI-1) [62], an inhibitor of
K. Mavridis et al.
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uPA, whereas KLK3 can directly activate MMP2 from its pre-
cursor (pro-MMP2) [63]. Finally, the identification of uPAR as
a direct substrate of KLK4 [64] highlights a possible key regula-
tory role of KLK4 on uPA-uPAR system-related proteolysis
and cell adhesion interaction with vitronectin and integrins.
EMT represents a hallmark cellular process of the progres-
sion of epithelial solid cancers. Both KLK3 and KLK4 have
been revealed to promote EMT-like changes in prostate
tumours. More precisely, transformation of PC3 to overexpress
KLK3 and KLK4 resulted in suppressed E-cadherin and
enhanced vimentin expression, increased migration potential
and spindle-shaped morphology [37,65]. Similar EMT-like
changes are also triggered in CaP cells by the overexpression
of KLK7 [66].
KLK1, which possesses kininogenase activity, promotes
angiogenesis via the production of kinin and the subsequent
activation of kinin B12 and B2 receptors [67,68], whereas an
angiogenesis preventing role has been attributed to KLK3.
Increased angiogenesis has been observed in CaP specimens
with downregulated KLK3 levels [69]; KLK3 reduces endothe-
lial cells proliferation and migration, attenuates their
responses to the angiogenesis stimulators fibroblast growth
factor-2 (FGF2) and VEGF and reduces metastatic disease
in mouse models [70,71].
Finally, KLK3 has been documented to facilitate bone mar-
row metastasis of CaP [72,73]. Using antibody-mediated block-
age of KLK3 or siRNA-mediated knockdown of KLK3
expression, CaP cells adhesion to bone marrow endothelial
cells was significantly diminished [74]. The bone metastasis
promoting role of KLK3 is also supported by the parathyroid
hormone-related protein and latent TGF-b cleavage. Simi-
larly, the upregulation of KLK4 expression in CaP cells during
their co-culture with the osteoblastic-like SaOs cell line pro-
motes their enhanced attachment to bone matrix proteins [75].
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Figure 2. The implication of KLKs in prostate cancer pathobiology and the various approaches of inhibiting and exploiting
KLK activity and/or expression for the development of novel therapeutics are shown. KLKs promote prostate cancer
development and progression via AR transactivation, ECM degradation, stimulation of the uPA-uPAR-MMPs pathway, the
IGF-IGFR axis, PARs activation and EMT facilitation. Approaches for exploiting KLKs as therapeutic targets include a variety of
synthetic KLK inhibitors, activation of pro-drugs, KLK-related immunotherapy, KLK3-based imaging and reprogramming KLK
expression trough RNA interference.
*Indicates that the therapeutic agent has entered clinical trials for prostate tumours.
AR: Androgen receptor; ECM: Extracellular matrix; EMT: Epithelial-to-mesenchymal transition; IGF: Insulin-like growth factor; IGFBP: IGF binding protein;
IGFR: IGF receptor; KLK: Tissue kallikrein and kallikrein-related peptidase; MMPs: Matrix metalloproteinases; PARs: Protease-activated receptors;
uPA: urokinase-type plasminogen activator; uPAR: uPA receptor.
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4. Inhibiting and exploiting KLK activity:
applications for CaP management
KLK inhibitors can be divided into naturally occurring/
endogenous inhibitors and engineered synthetic inhibitors.
Apart from the easily perceptible advantages of inhibiting
KLKs centrally involved in pathophysiological conditions
(Table 1, Figure 2), other ways of utilising KLK activity, such
as KLK-mediated activation of pro-drugs, KLK-directed
immunotherapy and KLK-based clinical imaging
Table 1. Summary of therapeutic approaches based on KLK inhibitors and KLK-targeting aptamers.
Type/agent Target Relevance Description/therapeutic impact Ref.
Engineered KLK inhibitors
Protein- and peptide-based inhibitors
SERPIN-type inhibitors
MDPK67b KLK2, 4, 14 Prostate
cancer
Bio-scaffolding produced ACT-based
inhibitor. Dose-dependent inhibition of
prostate tumour growth in mouse
xenografts. Evaluation in first-in-human trials.
[89,90]
DM107 Multi-KLK Skin
diseases
Bio-scaffolding produced ACT-based
inhibitor. Under investigation for
lymphoepithelial Kazal-type-related
inhibitor-associated skin diseases.
[89]
Naturally occurring proteinaceous-type
inhibitors
SFTI-FCQR-Asn14 KLK4 Prostate
cancer
Bio-scaffolding produced SFTI-based inhibitor/
Stable in prostate cancer cell cultures.
[91]
SFTI-WCTF KLK7 NA Bio-scaffolding produced SFTI-based inhibitor [92]
Short peptides inhibitors
Benzyloxycarbonyl-Ser-Ser-Lys-Leu-(boro)Leu KLK3 Prostate
cancer
Peptidyl boronic acid inhibitor/restricting the
development of subcutaneous prostate
cancer xenografts
[94]
Ahx-FSQn(boro)Bpg KLK3 Prostate
cancer
Peptidyl boronic acid inhibitor/retardation of
tumour growth and reduction of
prostate-specific antigen serum levels in
in vivo animal models
[95]
P3-D-Phe-conjugated synthetic peptides,
L-4-aminomethylphenylalanine-conjugated
synthetic peptides
KLK1 NA Synthetic peptide-based inhibitors [15,96]
FE999024 KLK1 Various
diseases
KLK1-specific peptide-based inhibitor. Inhibits
the invasion of breast cancer cells (ex vivo
model). Also showed promising results
against allergic inflammation, virus-induced
lung inflammation and acute pancreatitis
[15,16]
Pure peptides KLK2 NA Pure peptide inhibitors optimised by
cyclisation
[15,96]
Antibodies
DX-2300 KLK1 Asthma Anti-KLK1 monoclonal antibody/under
investigation for the treatment of asthma
[97]
Small-molecule inhibitors
Nitrogen-containing heterocyclic
compounds
KLK7 Skin
diseases
Under investigation for potential application
in skin diseases. Promising results in animal
models.
[16]
2-Azetidinone and triazole compounds KLK3 NA Monocyclic b-lactam derivative
(2-azetidinone). Triazole compounds
identified by the screening of a chemical
library of 50,000 compounds
[98,99]
1,2,4-Triazole derivatives KLK5, 7, 14 Skin
diseases
Potential usefulness for skin diseases, not
cytotoxic to healthy human keratinocytes
[100]
Nucleic acid aptamers
RNA, DNA aptamers KLK3, 6 NA Synthetic DNA or RNA molecules selected
from pools of random-sequence
oligonucleotides to specifically bind protein-
and peptide-targets
[102-104]
ACT: a1-antichymotrypsin; KLK: Tissue kallikrein and kallikrein-related peptidase; NA: Study not available yet; SFTI: Sunflower trypsin inhibitor.
K. Mavridis et al.
6 Expert Opin. Ther. Targets (2014) 18(4)
Ex
pe
rt 
O
pi
n.
 T
he
r. 
Ta
rg
et
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f N
ew
ca
stl
e 
on
 0
3/
12
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
(Table 2, Figure 2), can aid in confronting human pathologies
and especially CaP.
In this part, we summarise the currently available approaches
for inhibiting, enhancing and making use of KLK activity, cen-
tring the interest in CaP and therefore in KLKs1 -- 4, 7 and 14.
4.1 Nature’s repertoire for controlling KLK activity:
metal ions, proteinaceous and other molecules act-
ing as KLK inhibitors
Having in mind the broad physiological role of KLKs and the
permanent nature of protein hydrolysis, it is logical to
hypothesise that evolutionary pressure has led to a variety of
mechanisms for restricting unnecessary proteolysis by KLKs.
At the protein activity level, this is reflected by the expression
of all KLKs as inactive precursors (zymogens) [13], as well as by
the noticeable occurrence of diverse endogenous inhibitors,
including large proteinaceous molecules and metal ions.
Naturally occurring KLK inhibitors that are produced in
plants or bacteria comprise proteinaceous substances, low-
molecular-weight peptides and non-peptide agents.
4.1.1 Inhibition by Zn2+
It is well established that endogenous cations can regulate KLK
activity. The most remarkable regulation comes from Zn2+,
which can inhibit KLKs 2 -- 5, 7, 8, 12 and 14, and thus it is
considered as a central, reversible regulator of KLK activity,
especially for CaP-related KLKs [15]. Prostatic fluid contains
the highest concentration of Zn2+ in the human body [76],
which inactivates KLKs; however, during ejaculation, it is
mixed with epididymal fluid, containing high amounts of
semenogelins that effectively bind Zn2+. This leads to KLK
activation, semenogelin cleavage and semen liquefaction [13,77].
A characteristic of malignant prostate is the significant decrease
of Zn2+ concentration [78]. It would be logical to hypothesise
that one of the tumour-progression mechanisms in CaP could
be that decreased Zn2+ levels lead to aberrant activation of
CaP-promoting KLKs. Given the already studied tumour-
suppressor properties of Zn2+ in CaP, restoration of Zn2+ levels
has already been considered as a potential CaP therapy [78].
Considering that the systemic administration of Zn2+ can
introduce toxicity to multiple tissues, the intratumoral injec-
tion of Zn2+ comprises a more promising therapeutic strategy.
This approach has been shown to reduce prostate tumour
growth in mice models and to extend survival periods, without
causing toxicity issues in other organs [79].
4.1.2 Proteinaceous inhibitors
The most studied proteinaceous inhibitors are SERine Prote-
ase INhibitors (serpins), Kazal-type inhibitors and Kunitz-
type inhibitors. These inhibitors can obstruct KLK activity
by two main mechanisms: i) the canonical mechanism
(Kazal-type, Kunitz-type inhibitors) that includes direct com-
petition with the substrate for binding to the active site; and
ii) the irreversible ‘spring-suicide’ mechanism (serpins), which
includes insertion of the inhibitor’s reactive loop in the active
site, cleavage of the serpin--peptide bond, rearrangement of
both the protease’s and the inhibitor’s structure and, ulti-
mately, disruption of the catalytic triad [10,15,80].
Serpins occupy a notable portion of the human serum and
can inhibit most of the KLK members. Focusing on CaP-
related KLKs, KLK2 is inhibited by antithrombin III (AT),
a2-antiplasmin (AP), proteinase C inhibitor (PCI), proteinase
inhibitor 6 (PI-6) and PAI-1. Interestingly, KLK2--PI-6 com-
plexes are indicative of tissue damage and necrosis in CaP,
whereas the KLK2--PAI-1 complex hampers the inactivation
of uPA by PAI-1, thus favouring CaP progression.
KLK3 activity can be blocked by a1-antitrypsin (AAT), a1-
antichymotrypsin (ACT), PCI and the monocyte/neutrophil
elastase inhibitor. KLK4 serpin inhibitors are AAT and
ACT. KLK7 and KLK14 are inhibited by AAT, ACT, AP,
PCI and kallistatin; KLK14 is additionally inhibited by AT.
Moreover, KLK1 is strongly inhibited by kallistatin [15,80,81].
Recently, the visceral adipose tissue-derived serpin (vaspin or
serpinA12) was shown to target KLK7 [82].
The relationship between Kazal-type inhibitors and KLKs
has been made apparent from studies in Netherton syndrome
(NS), a genetic disease manifested by excessively disrupted
skin homeostasis. NS is associated with mutations in the serine
peptidase inhibitor Kazal-type 5 (SPINK5) gene, encoding for
the lymphoepithelial Kazal-type-related inhibitor (LEKTI),
that lead to insufficient KLK blocking and thus KLK hyperac-
tivity [12,15]. Interestingly, there have been reported cases of
NS patients who developed multiple skin malignancies [83].
LEKTI is processed to produce 15 individual subunit fragments
that can differentially modulate KLKs 5 -- 7, 13 and 14 [15].
Recent data show that the CaP-associated SPINK1 was found
to inhibit KLK2 [84].
The most studied Kunitz-type inhibitor is aprotinin or
bovine pancreatic trypsin inhibitor which was initially found
to inhibit KLK1, but later was found to inhibit also KLKs 2,
4, 5, 12 and 14 [10,15]. Plants also produce potent Kunitz-type
inhibitors; notably, the soybean trypsin inhibitor inhibits
KLKs 4 -- 6 and 14 [15]. Kunitz-type inhibitors are also produced
by the human organism [80]. Other, canonical, non-selective,
proteinaceous KLK inhibitors include elafin-like protease inhib-
itor antileucoprotease (inhibiting KLK7), the medical leech
(Hirudo medicinalis)-isolated hirustasin (inhibiting KLK1) [15]
and the sunflower trypsin inhibitor(SFTI) (blocking KLK4) [80].
Regarding lower-molecular-weight naturally occurring
agents, cyclic depsipeptides, produced from the cyanobacteria
Chondromyces represent the most promising agents and are
under investigation by Novartis AG as potent KLK7
inhibitors [10,15].
4.2 Resynthesizing nature’s regulatory molecules:
engineered KLK inhibitors as emerging therapeutics
Naturally occurring KLK inhibitors described in Section
4.1 cannot be considered as ready-to-use therapeutics; despite
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Table 2. Summary of therapeutic approaches based on KLK activation of pro-drugs, KLK-driven immunotherapy
and KLK-related imaging.
Type/agent Target Relevance Description/therapeutic impact Ref.
Activation of pro-drugs
L12ADT-based KLK2 Prostate
Cancer
Chemically modified form of a
thapsigargin analogue (L12ADT)
conjugated with a KLK2-cleaved
heptapeptide/inhibition of CaP cell lines
in vitro growth and anti-tumour effect in
corresponding in vivo models
[106]
L-377,202 KLK3 Prostate
Cancer
Doxorubicin conjugated with
KLK3-cleaved peptide/restrained prostate
tumour growth in in vivo animal models
and decreased toxicity compared to
doxorubicin in KLK3-negative cells. Phase I
clinical trials.
[107,110]
PRX302 KLK3 BPH Aerolysin conjugated with a KLK3-cleaved
peptide/intraprostatic administration in
BPH patients. Phase II clinical trials.
[108,111]
TGX-D1-based KLK3 Prostate
Cancer
Conjugated PI3K-b inhibitor TGX-D1 with
a KLK3-cleaved peptide and the N
terminus human epidermal growth factor
receptor 2-binding domain
[112]
LY294002-based KLK3 Prostate
Cancer
Chemically modified form of quercetin
(PI3K inhibitor) with a KLK3-cleaved
peptide/induction of apoptosis in prostate
cancer cells
[113]
BSD352-based KLK3 Prostate
Cancer
Anti-VEGF and anti-fibroblast growth
factor peptides, conjugated with a
KLK3-cleaved sequence/reduced tumour
growth, induced apoptosis and anti-
angiogenic properties in in vitro and
in vivo studies
[114]
L12ADT-based KLK3 Prostate
Cancer
Chemically modified form of a
thapsigargin analogue (L12ADT)
conjugated with a KLK3-cleaved peptide
[115]
D-arginine octamer
protein-transduction
domain-based
KLK3 Prostate
Cancer
D-arginine octamer protein-transduction
domain conjugated with a KLK3-cleaved
peptide/vector for the increase drug
uptake by prostate cancer cells
[116]
Immunotherapy
PROSTVAC KLK3 Prostate
Cancer
Pox viral-based vaccine expressing
KLK3 and three major T-cell co-
stimulatory molecules (TRICOM)/inhibition
of prostate cancer cell proliferation and
tumour growth, increased overall survival
and reduction in the risk of death.
Phase III clinical trials.
[120-124]
Anti-KLK3 engineered antibodies KLK3 Prostate
Cancer
Anti-KLK3 antibodies/induced T-cell
stimulation and anti-tumour response
towards prostate cancer cells
[125-127]
5-fluoro-2¢-deoxyuridine
anti-KLK3 IgG immunoconjugate
KLK3 Prostate
Cancer
Anti-KLK3 antibodies conjugated with the
chemotherapeutic agent 5-fluoro-2¢-
deoxyuridine/enhanced KLK3 expressing
tumour-specific cell death
[128]
KLK3-based clinical imaging tools
125I-anti-KLK3 mAb KLK3 Prostate
Cancer
125I-labelled monoclonal antibody against
free KLK3/effective targeting of free
KLK3 in LNCaP mouse xenografts
[132]
Carbobenzyloxy-Ser-Ser-
Gln-Nle-(boro)-Leu
KLK3 Prostate
Cancer
Carbobenzyloxy-Ser-Ser-Gln-Nle-(boro)-
Leu conjugated with a bulky metal
chelating group
[133]
ADT: Androgen deprivation therapy; BPH: Benign prostatic hyperplasia; KLK: Tissue kallikrein and kallikrein-related peptidase; PI3K: Phosphoinositide 3-kinase
inhibitor.
K. Mavridis et al.
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their great inhibitory capacity, they are characterised by
reduced selectivity. Their application as therapeutic agents
demands rational structure redesigning. Apart from improved
selectivity, an ideal pharmaceutically relevant KLK inhibitor
should encompass the following essential properties: i) a
favourable Absorption, Distribution, Metabolism, Excretion,
Toxicity (ADMET) profile [85]; ii) a low immunogenicity
potential [86]; iii) a stable structure that will yet retain all nec-
essary post-translational modifications [87], iv) high yield and
low cost during production upscaling [88]; as well as v) a
tissue-specific action.
Interestingly, the approach of bio-scaffolding, that is, the
use of endogenous inhibitors as scaffolds for engineered drugs,
has provided the first KLK inhibitor (MDPK67b, Med
Discovery) ever to reach first-in-human trials for evaluation
as a novel CaP drug [89,90].
4.2.1 Protein- and peptide-based inhibitors:
bio-scaffolding, short peptides and antibodies
MDPK67b is a restructured serpin-type inhibitor manufac-
tured by Med Discovery as a potential CaP therapeutic agent.
The basic bio-engineering principle that was followed was the
replacement of the favourably accessible reactive site loop of
the human serpin ACT with a cleavage site-bait region recog-
nised by KLK2. MDPK67b emerged as the lead compound,
inhibiting the CaP-related KLK2, KLK4 and KLK14. Mouse
xenograft models bearing DU145-induced KLK2-overex-
pressing tumours were used as a relevant in vivo model to
test the efficacy of MDPK67b; it has been reported that this
animal model has KLK2 serum levels comparable to those
measured in CaP patients. First, it was shown that KLK2 over-
expression led to the formation of more rapidly growing
tumours, corroborating in this way the role of KLK2 in CaP
progression in vivo. A MDPK67b dose-dependent inhibition
of prostate tumour growth, reaching up to approximately
90%, was observed. Toxicity studies were carried out in
appropriate animal models, including rodents and primates,
and MDPK67b showed a favourable toxicity and immunoge-
nicity profile [89,90]. These encouraging results led to the
launch of first-in-human clinical trials by Med Discovery in
order to investigate the safety, pharmacokinetic and pharma-
codynamic profiles of MDPK67b; the ultimate objective is
to evaluate this KLK inhibitor as a novel drug for asymptom-
atic CRPC patients [89]. The so far successful route of
MDPK67b can be attributed to the plasticity of ACT’s reac-
tive loop and to its low immunogenicity, arising from the
endogenous nature of ACT [80,89,90]. The biotech company
Dermadis has also exploited ACT as a bio-scaffold for build-
ing a multi-KLK inhibitor (DM107) for LEKTI-associated
skin diseases [89].
The bioavailable and cell-penetrating 14 amino acid SFTI
has also been remodelled by substituting a selected tetrapep-
tide into the bio-scaffold. The finally selected variant
SFTI-FCQR-Asn14 is a very potent, selective, stable in CaP
cell cultures and bioavailable KLK4 inhibitor [91]. Recently,
a novel and potent SFTI-based KLK7 inhibitor, termed
SFTI-WCTF, was also developed [92].
Short peptides that are themselves KLKs or mimic natural
substrates of KLKs can also be chemically modified to achieve
KLK inhibition. A series of synthetic peptide aldehydes, pep-
tidyl boronic acids, b-lactam-based inhibitors and azapeptides
have been evaluated as KLK3 inhibitors [93]. Of interest is the
benzyloxycarbonyl-Ser-Ser-Lys-Leu-(boro)Leu inhibitor,
which has an effect, although limited, in restricting the devel-
opment of subcutaneous CaP xenografts [94]. Recently, Ahx-
FSQn(boro)Bpg, a peptidyl boronic acid-based potent and
selective KLK3 inhibitor, containing a bromopropylglycine
group, was produced. This compound was shown to generate
a significant alteration in KLK3 serum levels of in vivo animal
models but had only a minimal effect in tumour growth [95].
Synthetic peptide-based inhibitors, containing a P3-D-Phe
residue or the non-natural amino acid L-4-aminomethylphe-
nylalanine, as well as the FE999024 peptidic inhibitor have
been shown to block KLK1 activity. KLK2 pure peptide
inhibitors have also been identified and were further opti-
mised, in terms of inhibition capacity and stability, by peptide
cyclisation [15,96].
Antibodies have also been used to block KLK activity. The
major advantage of this approach is that other protein areas,
apart from the active site, can be targeted, thus enhancing in
this way the inhibitor’s selectivity. Anti-KLK deactivating
antibodies have been developed for KLK1, KLK4, KLK6,
KLK12 and KLK13 [15,16,80]. The anti-KLK1 human mono-
clonal antibody DX-2300, developed by Dyax, holds promise
as a potential therapeutic agent for asthma [97].
4.2.2 Small-molecule inhibitors
Several small-molecule KLK inhibitors that could prove to
possess therapeutic properties have been identified. The
monocyclic b-lactam derivative 2-azetidinone has been
described as a potent KLK3 inhibitor [98]. Using high-
throughput screening of chemical libraries, two compounds
of the triazole family were identified as the most promising
in terms of non-toxic KLK3 inhibition [99]. Recently, several
promising 1,2,4-triazole derivatives that inhibit KLK5,
KLK7 and KLK14 were identified [100]. KLK7 can be effec-
tively targeted by nitrogen-containing heterocyclic com-
pounds that show very encouraging results in alleviating key
pathological events observed in skin diseases [16]. Finally,
KLKs 1 and 6 can also be potently inhibited by recently devel-
oped aminopyridine derivatives and N-(4-aminomethyl-
phenyl)-2-hydroxy-benzamides, respectively [16].
4.3 Nucleic acid aptamers: a new class of KLK
targeting compounds
Aptamers are synthetic DNA or RNA molecules selected from
pools of random sequence oligonucleotides to specifically
bind protein or peptide targets. The binding affinities of
aptamers are close to those of antibodies, whereas their small
size, engineering plasticity and uncomplicated synthesis
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make them attractive as novel protein-targeting therapeutics.
Aptamers can be conjugated with polyethylene glycol, toxins
or fluorescent moieties in order to get excluded by renal filtra-
tion, to act as targeted drugs, or to be used as detection
reagents, respectively [101]. Active KLK3 can be selectively tar-
geted by a selected RNA aptamer [102], whereas DNA
aptamers can be used to quantify KLK3 levels through biosen-
sors [103]. KLK6 can also be potently targeted by two recently
developed highly stable DNA aptamers [104].
4.4 Activation of pro-drugs from KLKs: exploiting
tissue-specific KLK activity to induce targeted CaP
toxicity
Pro-drugs can be developed in order to achieve tissue-specific
and, even better, cancer microenvironment-specific activity of
toxic drugs and thus optimal tumour inhibition with minimal
systemic toxicity [105]. In case of KLKs, the pro-drugs that
have been developed can be generally described as non-toxic
conjugates of peptide sequences, selectively recognised by
KLK2 or KLK3, with commonly used cytotoxic agents. The
relevant mechanism of action includes site-directed release of
the cytotoxic substance specifically in the cancer milieu where
KLK activity is evident. KLK activated pro-dugs hold prom-
ises as a novel targeted therapy for CaP.
Given the clear CaP-promoting role of KLK2 [18], this KLK
may not only be viewed as a good candidate for targeted CaP
therapy but it can also itself target pro-drugs to provide selec-
tive toxicity. A KLK2 heptapeptide substrate has been conju-
gated with an analogue of the toxic, non-specific, apoptosis-
inducing ATPase pump inhibitor thapsigargin, named
L12ADT. The synthesised pro-drug has been shown to
inhibit the in vitro growth of CaP cell lines expressing
KLK2 and also has been shown to retain a significant anti-
tumour effect in corresponding in vivo models; nonetheless,
prolonged intravenous administration caused local vein
toxicity [106].
The arsenal of KLK3-activated pro-drugs against prostate
tumours is far more thriving and advanced, given that some
of these substances have already been successfully evaluated
in Phase I and Phase II clinical trials [107,108]. Active
KLK3 is found almost exclusively in prostate tissue and serum
KLK3 activity is often blocked by serpins and other inhibi-
tors [13]. Consequently, a highly targeted drug delivery is
guaranteed via the pro-drugs approach. Parts of naturally
occurring KLK3 substrates, such as semenogelin I and seme-
nogelin II [13] have been optimised and conjugated with the
anthracycline doxorubicin, which represents an extensively
used chemotherapeutic agent [109]. The most promising of
these engineered compounds is L-377,202 [107]. Initial experi-
ments showed that L-377,202 had just the right properties to
be considered as a promising CaP therapeutic agent: it exhib-
ited decreased toxicity compared to doxorubicin in
KLK3-negative cells, whereas at the same time it showed far
more potency in restraining prostate tumour growth of
in vivo animal models [110]. An initial Phase I clinical trial
demonstrated that L-377,202 was well tolerated and a safe
dose was established for Phase II studies [107]. Cyclophospha-
mide, vinblastine, 5-fluoro-2¢-deoxyuridine and paclitaxel
have already been used for the production of analogous
KLK3-activated pro-dugs [109].
PRX302 is another KLK3-activated pro-drug that has been
designed for non-systemic administration in patients suffering
from benign prostatic hyperplasia (BPH). PRX302 can be
described as an engineered aerolysin. Aerolysin is a natural
cytolytic protein, synthesised by the bacterium Aeromonas
hydrophila as proaerolysin, an inactive proform that binds to
cell surface. Once bound, proaerolysin is activated via cleavage
of its inhibitory domain by membrane-located proteases; the
active aerolysin forms oligomers, which penetrate the cell
membrane forming stable pores, thus inducing instant cell
death. In PRX302, the inhibitory domain of proaerolysin
has been replaced by a KLK3-cleavable peptidic sequence,
leading to active KLK3 site-specific anti-tumour action [111].
Phase I and II clinical trials have already been performed
and have provided evidence that show the safety and the effi-
cacy of the intraprostatic administration of PRX302 in BPH
patients [108].
Moving to the preclinical level, another pro-drug has been
developed containing: i) a N terminus human epidermal
growth factor receptor 2 (HER2)-binding domain; ii) a
KLK3-cleavable peptide; and iii) the chemotherapeutic phos-
phoinositide 3-kinase (PI3K) b inhibitor TGX-D1. When
this multi-component peptide--drug conjugate is adminis-
tered to CaP cells in vitro, it binds to HER2 located on
cell surface. After that, endogenous KLK3 cleaves the peptide
sequence to release NH2-S-L-TGX which is then transported
into CaP cells, via peptide transporters, and a self-cyclisation
process occurs to produce TGX-D1. Interestingly, this bio-
construct shows an enhanced uptake rate, compared to the
parent drug TGX-D1 [112]. In an analogous approach, a
CaP-specific PI3K inhibitor was produced via conjugation
of the chemically modified form of the quercetin analogue
LY294002 with a KLK3-cleavable peptide. The resulting
pro-drug can effectively promote KLK3-dependent PI3K
inhibition, accompanied by induction of apoptosis in CaP
cells [113].
In another approach, BSD352, a complicated fusion pep-
tide construct was built by incorporating the following parts:
a cell-penetrating domain of the HIV transactivating regula-
tory protein, a BH3 domain of p53, an anti-VEGF peptide,
and an anti-basic FGF peptide. The different parts of
BSD352 have been conjugated with a KLK3 substrate in a
pro-drug that was found to induce apoptosis in CaP cells, as
well as to have anti-angiogenic properties and to inhibit
tumour growth both in vitro and in vivo [114].
As in the case of KLK2, the thapsigargin analogue
L12ADT was added to a KLK3-recognised substrate in order
to produce a pro-drug for CaP with potent and highly selec-
tive in vitro and in vivo action without any apparent host
K. Mavridis et al.
10 Expert Opin. Ther. Targets (2014) 18(4)
Ex
pe
rt 
O
pi
n.
 T
he
r. 
Ta
rg
et
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f N
ew
ca
stl
e 
on
 0
3/
12
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
toxicity [115]. Another KLK3-based approach that could be
used to increase targeted drug uptake by CaP cells has been
described. The D-arginine octamer protein-transduction
domain (positively charged) was conjugated with a peptide
recognised by KLK3 and an octamer-polyanionic segment.
Upon KLK3-mediated cleavage, the D-arginine octamer
domain enters the cells. The desired drug could be attached
to the protein transduction site and thus this system could
serve as an effective transporter for the targeted molecular
delivery of drugs into CaP cells [116].
Peptide-based activators, pseudopeptide ana-
logues [96,117,118] and antibodies that stabilise KLK3 in its
enzymatically active conformation [119] have also been devel-
oped. Given the Janus-like behaviour of KLK3 in CaP pro-
gression/suppression [18], it is difficult to safely conclude if
patients would actually benefit from a KLK3 modifying treat-
ment. Nonetheless, activators of KLK3 could be as well used,
after optimisation, in order to enhance the pro-drug activator
capacity of KLK3.
4.5 KLKs and immunotherapy: a novel approach for
CaP treatment
Immunotherapeutic strategies have drawn the attention as a
promising CaP treatment option, especially after the first-
ever FDA approval for a therapeutic cancer vaccine, that is,
sipuleucel-T [120].
PROSTVAC is a KLK3-based immunotherapeutic plan
currently under evaluation in Phase III clinical trials
(NCT01322490) for asymptomatic or minimally symptom-
atic, chemotherapy-naı¨ve, metastatic CRPC patients [121,122].
PROSTVAC is a pox viral-based vaccine which expresses
KLK3 and three major T-cell co-stimulatory molecules,
known as TRICOM, that is, B7.1 (CD80), lymphocyte
function-associated antigen-3, and intracellular adhesion mol-
ecule-1.The general mechanism of action of PROSTVAC
relies on the endowment of antigen-presenting cells with
KLK3 epitopes and the subsequent activation of cytotoxic
T cells (CD8+) and helper T cells (CD4+) that orchestrate
an attack on KLK3-expressing CaP cells. As a result, both
CaP cell proliferation and tumour growth rates are signifi-
cantly reduced [120-124]. Phase II clinical studies have shown
that despite there being no benefit with regard to
progression-free survival, PROSTVAC resulted in an
8.5 months increase in overall survival and a 44% reduction
in the risk of death. Moreover, it was well tolerated by
patients [121-123]. Interestingly, in patients exhibiting longer
survival intervals, a decrease in T-regulatory action and
an increase in KLK3-mediated T-cell responses were
manifested [121].
Immunotherapeutic anti-KLK3-engineered antibodies
have also been described. A bispecific murine antibody target-
ing both human CD3 and KLK3 can arbitrate an anti-tumour
response towards CaP cells both in vitro and in vivo [125].
Another murine anti-KLK3 (IgG1) antibody can induce
significant antigen presentation by human dendritic cells
and can mediate CD4+ and CD8+ T-cell activation [126].
Recently, an anti-KLK3 IgE antibody was constructed and
shown to effectively induce T-cell stimulation and provoke
anti-tumour and pro-survival effects when administered in
in vivo mouse models [127].
Anti-KLK3 antibodies can also be conjugated with chemo-
therapeutic drugs and can enhance KLK3-expressing tumour-
specific cell death in vivo, as it has already been described for a
5-fluoro-2¢-deoxyuridine IgG immunoconjugate [128].
The study by Wilkinson et al. also introduces KLK4 as an
immunogenic molecule capable of inducing specific CD8+
cytotoxic T-cell responses in vitro, suggesting that
KLK4-based immunotherapeutic vaccines should warrant fur-
ther clinical investigation for CaP patients. Interestingly,
potentially immunogenic peptide sequences, similar to that
of KLK4, can be also found in other members of the KLK
family [129].
4.6 KLK3 as a potential clinical imaging tool for
prostate tumours
Optimised imaging techniques could be used to selectively
detect the presence of malignant prostatic regions, extra pros-
tatic growth and metastatic sites [130].
Monoclonal anti-KLK3 antibodies labelled for imaging
purposes have been reported since 1987 [131], although they
have showed limitations such as high liver uptake, high activ-
ity in blood and non-specific background signal [131,132].
A recently developed 125I-labelled monoclonal antibody
against free KLK3 showed, using Digital Auto Radiography,
effective targeting of free KLK3 in LNCaP tumour-bearing
mice that was consistent with KLK3 expression sites. Target-
ing unbound KLK3 for imaging purposes could be more
effective compared to targeting complexed KLK3, because
free KLK3 is abundantly present proximal to its production
sites, whereas KLK3 complexed forms are mainly found in
blood circulation. Further evaluation of this technique is
needed in order to make it exploitable via positron emission
tomography (PET) or single-photon emission computed
tomography (SPECT) [132].
Aside from antibodies, KLK3 inhibitors or KLK3-based
pro-drug systems can be appropriately optimised to produce
useful imaging tools. More precisely, the boronic acid-type
KLK3 inhibitor carbobenzyloxy-Ser-Ser-Gln-Nle-(boro)-Leu
has been modified by the addition of a bulky metal chelating
group to the amino terminal end of this peptide. The fact that
this adjustment did not alter the inhibitory capacity of the
engineered compound suggests that it is highly promising
for potential use in PET- or SPECT-based imaging strate-
gies [133]. Additionally, the KLK3-dependent protein-
transduction construct described previously (Section 4.4)
could be modified by the conjugation of an appropriate imag-
ing moiety, instead of an anticancer agent, as a cargo that
could be selectively delivered inside CaP cells [116].
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5. Modulating KLKs expression: an
overlooked therapeutic approach?
As previously described, the expression of the majority of
KLKs is significantly deregulated in CaP and is thought to
promote tumour progression. Consequently, the restoration
of KLK expression, to a physiological state, represents an alter-
native and attractive KLK-targeting therapeutic approach for
CaP (Table 3, Figure 2).
RNA interference (RNAi) using small non-coding RNAs
represents the most essential cellular machinery for the post-
transcriptional regulation of specific gene expression [134,135].
The crucial mediators of RNAi-related gene regulation are
endogenous miRNAs, promoting gene silencing by partial
complementarity with target mRNAs, and exogenous siRNAs
or shRNAs requiring near-perfect base-pairing with target
sequences. Exploitation of the cellular RNAi machinery could
contribute to the targeted reprogramming of gene expression
in CaP.
5.1 siRNA- and shRNA-mediated KLKs silencing
Exogenous delivery of siRNAs and shRNAs for gene silencing
has been extremely used in cancer-related research in order to
elucidate the role of specific genes in cancer scene and their
potential therapeutic impact. Viral-based systems have been
extensively used for the intracellular delivery of siRNAs.
However, due to safety concerns, immunogenic and inflam-
matory responses and high production costs, non-viral
approaches, such as liposomes, polymers, nanoparticles, car-
bon nanotubes, atelocollagen and chemical modifications of
oligonucleotides for naked siRNAs delivery, have been suc-
cessfully used instead of viral-based constructs [136].
Focusing on CaP and KLKs, siRNA-/shRNA-mediated
knockout of KLK2, KLK3 and KLK4 restores their expression
levels in the prostate microenvironment and produces encour-
aging therapeutic effects both in vitro and in vivo. Transfec-
tion of LNCaP cells with siRNA against endogenous KLK2
leads to suppressed cell growth, accumulation of the cells in
G1 cell-cycle phase and activation of apoptosis in androgen-
independence disease stages. Additionally, significantly
smaller tumours were detected in LNCaP xenografts upon
stable expression of KLK2-targeting siRNA compared with
control ones, thus highlighting the in vivo therapeutic
dynamic for CRPC [54].
Similar benefits were also produced by a gene-specific
shRNA lentiviral construct targeting endogenous KLK3
expression in LNCaP cells. More precisely, transfection of
Table 3. Summary of therapeutic approaches based on the restoration of KLK expression.
Type/agent Target Relevance Description/therapeutic impact Ref.
Restoration of KLK expression
siRNA-/shRNA-mediated silencing
KLK2-targeting KLK2 Prostate Cancer Anti-KLK2-specific siRNAs/shRNAs/
suppressed cell growth, accumulation of
the cells in G1 cell-cycle phase and
activation of apoptosis in LNCaP cells.
Detection of smaller tumours in LNCaP
xenografts compared to controls
[54]
KLK3-targeting KLK3 Prostate Cancer Anti-KLK3-specific siRNAs/shRNAs/
inhibition of LNCaP cells growth rate and
reduced tumour weight and
KLK3 secretion of LNCaP xenografts.
Attenuation of C4-2B cells adhesion to
bone endothelium.
[59,74,137]
KLK4-targeting KLK4 Prostate Cancer Suppression of growth rate and
anchorage-independent growth of LNCaP,
LAPC4 and VCaP cell lines. Cell-cycle
arrest in G1 phase and increased
sensitivity to apoptosis in LNCaP cells.
Lower growth rate of LNCaP xenografts.
Suppression of androgen receptor
signalling in vitro and in vivo.
[38,55]
miRNA-mediated targeting
miR-331-3p KLK4 Prostate Cancer Experimentally validated miRNA able to
target KLK4/reduced cell proliferation of
DU-145.
[144]
miR-143 KLK10 Prostate Cancer Experimentally validated miRNA able to
target KLK10/reduced cell proliferation of
DU-145.
[144]
KLK: Tissue kallikrein and kallikrein-related peptidase; miRNA: microRNA; siRNA: Small-interfering RNA; shRNA: small hairpin RNAs.
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LNCaP cells in order to stably express shRNA constructs
against KLK3 significantly diminished their growth rate. An
in vivo study of shRNA-mediated KLK3 knockdown revealed
the significantly reduced tumour weight and KLK3 secretion
of LNCaP xenografts compared to control mice [137]. More-
over, KLK3 silencing by siRNA delivery introduces cell-cycle
arrest at the G1 phase and induction of apoptosis in CaP
cell lines in vitro, as well as suppression of growth rate of
in vivo xenografted tumours [59]. Based on the observation
that antibodies against KLK3 inhibit the adhesion of CaP cells
to bone marrow epithelial cells, siRNA-dependent silencing of
KLK3 in C4-2B androgen-independent cell line resulted in a
similar attenuation of C4-2B cell adhesion to bone endothe-
lium [74]. These data clearly highlight the beneficial therapeu-
tic use of siRNA-mediated silencing of KLK3 for the
prevention of CRPC bone metastasis.
Moreover, knockdown of KLK4 in LNCaP prostate cells
following siRNA transfection resulted in the significant sup-
pression of cell proliferation rate in vitro [38]. More recently,
the lentiviral-mediated stable expression of shRNA construct
against KLK4 in LNCaP, LAPC4 and VCaP prostate cell lines
was shown to reduce their growth rates and their anchorage-
independent growth. The in vitro therapeutic potential of
KLK4 silencing was, thereafter, confirmed in vivo by the lower
growth rate of xenografted prostate tumours. The impact of
KLK4 knockdown in CaP cells homeostasis revealed cell-cycle
arrest in G1 phase, as well as promotion of apoptosis, indicat-
ing the role of KLK4 silencing in sensitising CaP cells to
apoptosis-related therapies [55].
5.2 miRNA-mediated targeting of KLKs
The miRNAs have attracted great attention recently due to
their ability to regulate the expression of the vast majority of
human genes, their involvement in cell proliferation, differen-
tiation, signal transduction and apoptosis, their ability to con-
trol multiple targets and their deregulated expression in
human diseases and mainly cancer [138]. In CaP, microarray-
based studies have highlighted the deregulation of a great
number of miRNAs in tumour tissues compared to normal
or benign epithelium [139,140].
Several preclinical studies in CaP have pointed out the ther-
apeutic utility of miRNAs. Liposome-mediated delivery of
miR-34a, leads to the inhibition of tumour growth and lung
metastasis of CaP in mice, as well as to prolonged survival
periods following treatment. Delivery of miR-15a and
miR-16 to CaP xenografts was documented to reduce tumour
growth, whereas delivery of miR-16 or miR-203 in metastatic
CaP mouse models was able to inhibit the growth of tumours
in the bone marrow [141].
Using algorithm-based analyses, the majority of KLKs has
been predicted to be targeted by multiple miRNAs [142].
Among them, the regulation of KLK10 by let-7f, miR-224,
miR-516a and miR-143 [142-144], of KLK6 by let-7f [142], of
KLK1 by miR-224 [145], of KLK5 by miR-382 [146] and the
control of KLK4 by miR-331-3p [144] have already been
experimentally validated in human malignancies. Focusing
on CaP, transfection of DU-145 with miR-331-3p or
miR-143, which both are significantly downregulated in
CaP, resulted in decreased KLK4 and KLK10 expressions,
respectively, and in consequent reduction in cell prolifera-
tion [144]. These results clearly point out the tumour suppres-
sor role of the abovementioned miRNAs in CaP; in the case of
miR-331-3p, this is also supported by the prediction of KLK2
targeting. Additionally, miR-224, which is predicted to target
KLK15, is found significantly downregulated in CaP tissues,
compared to benign ones, and in more advanced CaP
tumours; miR-224 downregulation is also associated with bio-
chemical relapse [147].
The benefits of restoring CaP-related KLK expression via
miRNAs are their small, and thus less antigenic, size and their
ability to concurrently target several genes, which amplifies
their therapeutic impact. Several systems, such as liposomes,
miRNA conjugation to peptides able to bypass plasma mem-
brane and lentiviral vectors, have been successfully used for
the delivery of miRNAs to treatment sites. Nonetheless, the
fact that miRNAs target multiple and possibly unrelated genes
might be a disadvantage compared to siRNA-based
approaches.
6. Conclusion
KLKs have been broadly recognised, through continuously
reported clinically oriented and mechanistic research studies,
as a group of molecules that play a crucial role in the pathobi-
ology of human malignancies [11,12,17-19]. This holds true espe-
cially for CaP, where KLK members 1 -- 4, 7 or 14 are
involved in tumour growth, cell invasiveness, angiogenesis or
metastasis [18]. The important limitations of currently used
CaP therapeutics, for example, the inevitable development
of castrate resistance despite ADT, the systemic toxicity and
the limited survival benefit of chemotherapy, as well as the
high cost of immunotherapy [25], have driven researchers to
identify emerging drugs that could overcome these deficien-
cies. The broad inhibitory dynamics of KLKs and the rational
exploitation/modification of their activity and expression can
be considered as the basis of novel strategies for confronting
prostate malignancies.
7. Expert opinion
Aberrant proteolytic function has been identified as a crucial
event in numerous malignant and non-malignant human dis-
eases. Consequently, the therapeutic use of protease inhibitors
has been considered, studied and exploited extensively
throughout the years [148].
Protease inhibition has already been applied as a key thera-
peutic modality for several pathophysiological conditions,
with remarkable clinical and commercial success. The most
thriving examples include the utilisation of proteasome inhib-
itors for the treatment multiple myeloma and mantle cell
Targeting kallikrein-related peptidases in prostate cancer
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lymphoma, angiotensin-converting enzyme inhibitors for the
treatment of hypertension and congestive heart failure, HIV
protease inhibitors for treatment of HIV infections [148-150]
and ecallantide (trade name Kalbitor, Dyax Corp., investiga-
tional name DX-88), which is a re-engineered Kunitz-type
inhibitor against KLKB1, currently being used as a medica-
tion for acute hereditary angioedema attacks [148,151].
The well-reported therapeutic potential of KLK inhibitors
may also be translated into a clinical reality. Skin disorders
represent an ideal setting for using KLK inhibitors, as their
targets can be easily accessed during local drug application.
In fact, several KLK inhibitory compounds have shown prom-
ising results regarding skin diseases [10,16,89] and are expected
to enter clinical trials.
Regarding CaP, MDPK67b, an engineered ACT-based
multi-KLK inhibitor [89,90] (blocking KLK2, KLK4 and
KLK14 activity), has shown encouraging results in restraining
prostate tumour growth in mouse models. Toxicity studies in
rodent and primate models, as well as cynomolgus monkeys,
showed a favourable safety profile. These data led to the
launch of first-in-human studies for MDPK67b [89]. Results
are highly anticipated in the near future in order to find out
whether MDPK67b will be the first KLK inhibitor to be
used for CaP treatment. The bio-scaffold approach has
also been used for the production of a SFTI-based KLK4
inhibitor which shows great promise in terms of inhibitory
potency, selectivity and stability [91], whereas further work is
needed to evaluate its potential as a CaP therapeutic. Modi-
fied short peptides, antibodies, small molecule inhibitors
and aptamers that can block the activity of CaP-associated
KLKs (i.e., KLK1 -- 4, 7 and 14) and are described through-
out this review hold promise as novel CaP therapeutics.
Despite the fact that the abovementioned results are more
than encouraging for the future use of KLK inhibitory mole-
cules, we should always keep in mind the recent Phase III clin-
ical trial failures of several MMPs inhibitors, which were
initially regarded as promising cancer therapeutics. Possible
reasons for these abysmal failures included the inefficiency
of preclinical and target validation studies in predicting the
wide biological spectrum of MMPs inhibitors that also
blocked tumour-suppressor proteases and/or activated tumor-
igenic molecular pathways [152-154].
KLKs have long passed the era when they were considered
as one-dimensional proteolytic molecules and have entered
the world of cell signalling and protease crosstalk networks [13].
Consequently, a multidisciplinary approach might be more
relevant for the production of a new generation of KLK
inhibitors applicable for oncology, including CaP treatment.
The further elucidation of the physiological roles of KLKs as
well as the identification of new ones, combined with data
from crystallographic, three-dimensional structuring and bio-
informatics studies can lead to even more optimised KLK
inhibitors. Besides selectivity issues, which can be overcome
by exploiting the significant substrate specificities of KLKs
and re-engineering the already available repertoire of inhibi-
tory molecules, potential toxicity, industrialisation and com-
mercial strategies should also be considered.
Apart from KLK inhibition, KLK activation of pro-drugs
and KLK-based immunotherapy represent two very promis-
ing therapeutic strategies. Indeed, the KLK3-activated, doxo-
rubicin pro-drug L-377,202 [107] and aerolysin pro-drug
PRX302 [108] have gone through Phase I and Phase II clinical
trials, respectively: L-377,202 for the treatment of CaP and
for BPH [107,108]. What is more, the KLK3-based PROST-
VAC vaccine has already entered Phase III clinical trials for
evaluation as a novel immunotherapeutic for CaP [121,122].
In a more theoretical yet exciting approach, targeting the
gene expression of heavily upregulated KLK genes in CaP (e.
g., KLK4 [36], KLK15 [155] and KLK14 [156]) seems an alterna-
tive way to regulate KLKs. The recent clinical success of mod-
ified antisense oligonucleotides that target the expression of
the cytoprotective protein clusterin (OGX-011, OncoGeneX
Technologies) in Phase II trials and the commencement of
relevant Phase III trials pave the way for gene expression mod-
ifying therapeutics for CaP [157]. Overexpressed KLK genes
could also be considered as targets for CaP treatment via the
use of analogous constructs, including modified antisense oli-
gonucleotides, siRNA, shRNA and miRNA constructs.
We believe that the already suggested therapeutic modali-
ties and the ongoing both basic and clinical researches on
KLKs provide grounds for predicting that the first therapeutic
application of a KLK-based molecule will be a reality for CaP
treatment in the coming years.
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